ProPhase Labs, Inc. Common Stock, Capital Shares Reserved for Future Issuance
ProPhase Labs, Inc. (PRPH) had Common Stock, Capital Shares Reserved for Future Issuance of 2.96 million shares as of 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2023-03-29
- 2022-12-31: Common Stock, Capital Shares Reserved for Future Issuance 2.96M shares.
- 2022-06-30: Common Stock, Capital Shares Reserved for Future Issuance 1.60M shares.
- 2022-03-31: Common Stock, Capital Shares Reserved for Future Issuance 295.79K shares.
- 2021-12-31: Common Stock, Capital Shares Reserved for Future Issuance 275.79K shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance |
|---|---|
| 2022-12-31 | 2.96M shares 10-K · filed 2023-03-29 |
| 2022-06-30 | 1.60M shares 10-Q · filed 2022-08-12 |
| 2022-03-31 | 295.79K shares 10-Q · filed 2022-05-13 |
| 2021-12-31 | 275.79K shares 10-K · filed 2022-03-31 |
| 2014-03-31 | 767.49K shares 10-Q · filed 2014-05-12 |
| 2013-09-30 | 1.49M shares 10-Q · filed 2013-11-13 |
| 2013-06-30 | 1.49M shares 10-Q · filed 2013-08-13 |
| 2013-03-15 | 1.49M shares 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |